Altimmune, Inc. Announces Positive Phase 2 Topline Results for Pemvidutide

What Happened
Altimmune, Inc. (ALT) filed a Form 8-K on July 28, 2026 and issued a press release announcing positive topline results from the RECLAIM Phase 2 trial of pemvidutide 2.4 mg, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate-to-severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo and showed positive results across key secondary endpoints. The company reported a generally favorable safety and tolerability profile and plans to request an End-of-Phase 2 meeting with the FDA.

Key Details

• Trial: RECLAIM Phase 2 (pemvidutide 2.4 mg) in moderate-to-severe AUD; topline announced July 28, 2026.
• Primary endpoint: Highly statistically significant reduction in heavy drinking days per week (HDD) vs placebo.
• Secondary/registrational endpoints: Two-level reduction in WHO Risk Drinking Level and achievement of zero HDDs (both cited as FDA registrational endpoints); also observed reduction in phosphatidyl ethanol (PEth) levels.
• Safety: Reported generally favorable safety and tolerability.
• Next step: Company plans to request an End-of-Phase 2 meeting with the FDA.

Why It Matters
Meeting the primary and multiple FDA-relevant secondary endpoints in Phase 2 is a meaningful clinical milestone — it supports Altimmune’s intent to engage the FDA on next steps (End-of-Phase 2) and could pave the way for designing registrational/pivotal studies. For investors, these topline results may materially affect the perceived value and development timeline of pemvidutide as a potential treatment for AUD; the company’s stated regulatory engagement is the immediate next catalyst.